Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study
Anna Stoliaroff-Pepin, View ORCID ProfileCaroline Peine, Tim Herath, Johannes Lachmann, Wiebke Hellenbrand, Delphine Perriat, Achim Dörre, View ORCID ProfileAndreas Nitsche, View ORCID ProfileJanine Michel, Marica Grossegesse, Natalie Hofmann, Thomas Rinner, Claudia Kohl, View ORCID ProfileAnnika Brinkmann, Tanja Meyer, Daniel Stern, Fridolin Treindl, Brigitte G. Dorner, Sascha Hein, Laura Werel, Eberhard Hildt, Sven Gläser, View ORCID ProfileHelmut Schühlen, Caroline Isner, Alexander Peric, Ammar Ghouzi, Annette Reichardt, Matthias Janneck, Guntram Lock, Dominik Huster, Thomas Grünewald, Lars Schaade, Ole Wichmann, Thomas Harder
doi: https://doi.org/10.1101/2023.01.09.23284327
Anna Stoliaroff-Pepin
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Caroline Peine
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Tim Herath
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Johannes Lachmann
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Wiebke Hellenbrand
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Delphine Perriat
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Achim Dörre
2Department for Infectious Disease Epidemiology, Robert Koch Institute
Andreas Nitsche
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Janine Michel
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Marica Grossegesse
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Natalie Hofmann
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Thomas Rinner
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Claudia Kohl
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Annika Brinkmann
3Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute
Tanja Meyer
4Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute
Daniel Stern
4Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute
Fridolin Treindl
4Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute
Brigitte G. Dorner
4Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute
Sascha Hein
5Division Virology, Paul-Ehrlich-Institute
Laura Werel
5Division Virology, Paul-Ehrlich-Institute
Eberhard Hildt
5Division Virology, Paul-Ehrlich-Institute
Sven Gläser
6Klinik für Innere Medizin - Pneumologie und Infektiologie, Vivantes Klinikum Neukölln und Spandau, Berlin
Helmut Schühlen
7Vivantes Netzwerk für Gesundheit GmbH, Direktorat Klinische Forschung & Akademische Lehre, Berlin
Caroline Isner
8Klinik für Innere Medizin - Infektiologie, Vivantes Auguste-Viktoria-Klinikum, Rubensstr. 125, 12157, Berlin
Alexander Peric
9Klinik für Pneumologie und Infektiologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin
Ammar Ghouzi
10Schön Klinik Düsseldorf, Interdisziplinäre Notaufnahme, Am Heerdter Krankenhaus 2, 40549 Düsseldorf
Annette Reichardt
11Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin
Matthias Janneck
12Klinik für Kardiologie, Sektion Nephrologie, Albertinen Krankenhaus, Süntelstraße 11a, 22457 Hamburg
Guntram Lock
13Klinik für Innere Medizin, Albertinen Krankenhaus, Süntelstraße 11a, 22457 Hamburg
Dominik Huster
14Klinik für Innere Medizin, Helios Klinikum Erfurt
Thomas Grünewald
15Klinik für Infektions- und Tropenmedizin, Klinikum Chemnitz
Lars Schaade
16Centre for Biological Threats and Special Pathogens, Robert Koch Institute
Ole Wichmann
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Thomas Harder
1Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted January 09, 2023.
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study
Anna Stoliaroff-Pepin, Caroline Peine, Tim Herath, Johannes Lachmann, Wiebke Hellenbrand, Delphine Perriat, Achim Dörre, Andreas Nitsche, Janine Michel, Marica Grossegesse, Natalie Hofmann, Thomas Rinner, Claudia Kohl, Annika Brinkmann, Tanja Meyer, Daniel Stern, Fridolin Treindl, Brigitte G. Dorner, Sascha Hein, Laura Werel, Eberhard Hildt, Sven Gläser, Helmut Schühlen, Caroline Isner, Alexander Peric, Ammar Ghouzi, Annette Reichardt, Matthias Janneck, Guntram Lock, Dominik Huster, Thomas Grünewald, Lars Schaade, Ole Wichmann, Thomas Harder
medRxiv 2023.01.09.23284327; doi: https://doi.org/10.1101/2023.01.09.23284327
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study
Anna Stoliaroff-Pepin, Caroline Peine, Tim Herath, Johannes Lachmann, Wiebke Hellenbrand, Delphine Perriat, Achim Dörre, Andreas Nitsche, Janine Michel, Marica Grossegesse, Natalie Hofmann, Thomas Rinner, Claudia Kohl, Annika Brinkmann, Tanja Meyer, Daniel Stern, Fridolin Treindl, Brigitte G. Dorner, Sascha Hein, Laura Werel, Eberhard Hildt, Sven Gläser, Helmut Schühlen, Caroline Isner, Alexander Peric, Ammar Ghouzi, Annette Reichardt, Matthias Janneck, Guntram Lock, Dominik Huster, Thomas Grünewald, Lars Schaade, Ole Wichmann, Thomas Harder
medRxiv 2023.01.09.23284327; doi: https://doi.org/10.1101/2023.01.09.23284327
Subject Area
Subject Areas
- Addiction Medicine (392)
- Allergy and Immunology (705)
- Anesthesia (197)
- Cardiovascular Medicine (2882)
- Dermatology (247)
- Emergency Medicine (432)
- Epidemiology (12622)
- Forensic Medicine (10)
- Gastroenterology (813)
- Genetic and Genomic Medicine (4483)
- Geriatric Medicine (409)
- Health Economics (717)
- Health Informatics (2868)
- Health Policy (1059)
- Hematology (379)
- HIV/AIDS (911)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4250)
- Nursing (228)
- Nutrition (622)
- Oncology (2226)
- Ophthalmology (633)
- Orthopedics (255)
- Otolaryngology (323)
- Pain Medicine (270)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1182)
- Primary Care Research (487)
- Public and Global Health (6829)
- Radiology and Imaging (1502)
- Respiratory Medicine (908)
- Rheumatology (430)
- Sports Medicine (376)
- Surgery (476)
- Toxicology (60)
- Transplantation (206)
- Urology (176)